Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of occlusive 5-aminolevulinic acid (ALA) application in photodynamic therapy for actinic keratosis
2014-003331-18Phase 4Completed
- Sponsor
- Medical University of Vienna, Department of Dermatology
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of 5-aminolevulinic acid in actinic keratosis (AK) and non-melanoma skin cancer (NMSC), sponsored by Medical University of Vienna, Department of Dermatology. Primary endpoint: Complete clearance of actinic keratosis at 3 months. Started Nov 2014; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on 2014-003331-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003331-18.